Seneca Biopharma (formerly Neuralstem), a biopharma company engaged in developing treatments for diseases of high unmet medical need, has completed construction on its new cell manufacturing facility in Suzhou, China.

The cell manufacturing facility will be used  for manufacture NSI-566, the lead stem cell therapy of Seneca Biopharma for clinical trials in China, which includes a non-GCP compliant phase 2 trial, which is currently in progress for the treatment of chronic ischemic stroke at the BaYi Brain Hospital in Beijing.

Dr. Ken Carter – Executive Chairman of Seneca Biopharma said: “Completion of our new facility in Suzhou is a key milestone in Seneca’s product development strategy.

“This facility will allow us to manufacture cells to support our current and future clinical trials in China.” Further, Dr. Carter commented “I’d like to personally thank the staff who have been able to move forward on this plan while maintaining their safety during these uncertain times.”

  China, Dr. Ken Carter, Ischemic Stroke, Seneca Biopharma, Stem cell, Stroke